Number of the records: 1
Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases
- 1.0559907 - ÚOCHB 2023 RIV eng P - Patent Document
Slusher, B. - Rojas, C. - Thomas, A. G. - Nencka, Radim - Šála, Michal - Hřebabecký, Hubert
Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases.
2022. Owner: The Johns Hopkins University - Ústav organické chemie a biochemie AV ČR v. v. i. Date of the patent acceptance: 14.04.2022. Patent Number: AU2018205277
R&D Projects: GA MŠMT(CZ) EF16_019/0000729
Institutional support: RVO:61388963
Keywords : nSMase2 * Alzheimer’s disease * brain penetration
OECD category: Medicinal chemistry
https://worldwide.espacenet.com/patent/search/family/062791143/publication/AU2018205277B2?q=AU2018205277B2
Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) and their use for treating neurodegenerative diseases, such as, neurodegenerative diseases associated with high levels of ceramide, including, but not limited to Alzheimer's disease (AD), HIV-associated neurocognitive disorder (HAND), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), and, in other aspects, for treating cancer, are provided.
Permanent Link: https://hdl.handle.net/11104/0333032
Number of the records: 1